Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Prognosis of refractory neurosarcoidosis altered by thalidomide: a case report | Journal of Medical Case Reports BioMed Central Case report Open Access Prognosis of refractory neurosarcoidosis altered by thalidomide a case report J Chad Hoyle Herbert B Newton and Steven Katz Address Dardinger Neuro-Oncology Center Division of Neuro-Oncology and Department of Neurology The Ohio State University Medical Center and James Cancer Hospital Solove Research Institute Columbus Ohio USA Email J Chad Hoyle - Herbert B Newton - Steven Katz - Corresponding author Published 28 January 2008 Received 14 September 2007 Journal of Medical Case Reports 2008 2 27 doi 1752-1947-2-27 Accepted 28 January 2008 This article is available from http content 2 1 27 2008 Hoyle et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Sarcoidosis is a multisystem disease characterized by noncaseating granulomas in the lungs skin lymph nodes and rarely the nervous system. Granuloma formation in sarcoidosis is mediated by increased secretion of interferon-gamma interleukin-2 and tumor necrosis factoralpha. 25 of patients with neurosarcoidosis are steroid resistant and another 20-40 are resistant to any conventional immunosuppression but the typical agents suppress the immune system in a non-specific fashion. Thalidomide has been shown to have activity specific to the inflammatory mediators of sarcoidosis has been shown to be beneficial in cutaneous sarcoidosis and provides an interesting observation in our patient with refractory neurosarcoidosis. Case presentation A 40 year old African-american female presented with refractory neurosarcoidosis. Over the course of several years the patient was treated with high dose steroids .
